Private Company Edition: In other venture capital mega-rounds, Aurion brought in $120m, Sionna launched with $111m and Irish firm Renexxion said a private equity group committed up to $100m in total investment to be made within 36 months of a future public listing. 

The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.